Stoke Therapeutics, Inc. (STOK) Stock

Stoke Therapeutics, Inc. (STOK) is a Healthcare stock trading at $30.97 (as of 2026-06-18), with a market capitalization of $1.93B and a trailing P/E of -11.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Stoke Therapeutics, Inc. develops antisense oligonucleotide medicines aimed at addressing the underlying causes of severe genetic diseases. Its pipeline includes ASO candidates such as STK-001 for Dravet syndrome and STK-002 for autosomal dominant optic atrophy, and it operates through collaborations including a license and collaboration with Acadia Pharmaceuticals.

Valuation — source: SEC EDGAR (first-party)
Price	$30.97
Market Cap	$1.93B
P/E Ratio	-11.0
EV / EBITDA	-9.6
Price / Book	4.88
Price / Sales	60.01
DCF Value (model)	$14.35
DCF Upside vs Price	-53.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$184.42M
Net Margin	-3.7%
Return on Equity	-43.0%
Current Ratio	8.99
Revenue Growth (YoY)	404.5%
EPS Growth (YoY)	-92.7%
FCF Growth (YoY)	-151.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	15.98 (safe)

Valuation vs Sector & Industry
Stock P/E	-11.0
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-152.5%
vs Industry	-163.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RTW INVESTMENTS, LP ($183.10M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Ian F. Smith
Employees	128
Country	US
IPO Date	2019-06-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.